Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis

被引:26
|
作者
Kong, Pengyu [1 ]
Yan, Jinglong [1 ]
Liu, Donghui [2 ]
Ji, Ye [1 ]
Wang, Yufu [1 ]
Zhuang, Jinpeng [1 ]
Wang, Jincai [2 ]
Hu, Xiaowei [2 ]
Yue, Xiaolong [2 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, 246 Xuefu Rd, Harbin 150001, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Tumor Hosp, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
bone metastasis; nonsmall cell lung cancer; skeletal-related events; survival; LONG-TERM EFFICACY; ZOLEDRONIC ACID; RISK-FACTORS; DOUBLE-BLIND; CHEMOTHERAPY; EPIDEMIOLOGY; PREDICTORS; CARCINOMA; SAFETY; TUMORS;
D O I
10.1097/MD.0000000000009327
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because of improving treatments and survival, 40% to 58% of patients with bone metastases from nonsmall cell lung cancer (NSCLC) will suffer from at least one skeletal-related event (SRE), affecting their quality of life, but the natural history of SRE is poorly understood. The study aimed to examine the factors involved in SRE-free survival (SRS) and overall survival (OS) of patients with NSCLC and bone metastases.This was a retrospective study of 211 patients with bone metastasis from NSCLC and treated at the Tumor Hospital Affiliated to Harbin Medical University between January 2007 and January 2012. OS and SRS were evaluated by the Kaplan-Meier method. The factors associated with SRS and OS were examined using multivariate Cox analyses.The 1 year OS was 55.9% and the median OS was 30 months (range, 1-98 months). Multivariate analyses showed that clinical staging at initial diagnosis (P<.001) and SRE (P=.033) were independently associated with OS, and clinical staging at initial diagnosis (P=.009), bone pain (P=.008), primary tumor radiotherapy (P<.001), and chemotherapy (P=.031) were independently associated with SRS. Stage I, II, and III patients under biphosphonate therapy fared better than those without biphosphonate treatment, but there was no difference for stage IV patients.The identification of factors associated with OS and SRS of patients with NSCLC and bone metastases should provide new clues for a better management of these patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] The burden of skeletal-related events in patients with prostate cancer and bone metastasis
    Roghmann, Florian
    Antczak, Carina
    McKay, Rana R.
    Choueiri, Toni
    Hu, Jim C.
    Kibel, Adam S.
    Kim, Simon P.
    Kowalczyk, Keith J.
    Menon, Mani
    Nguyen, Paul L.
    Saad, Fred
    Sammon, Jesse D.
    Schmid, Marianne
    Sukumar, Shyam
    Sun, Maxine
    Noldus, Joachim
    Quoc-Dien Trinh
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 17.e9 - 17.e18
  • [2] Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis
    Tsuda, Yusuke
    Nakagawa, Tohru
    Shinoda, Yusuke
    Kanatani, Atsushi
    Kawai, Taketo
    Taguchi, Satoru
    Yamada, Yukio
    Sawada, Ryoko
    Kume, Haruki
    Homma, Yukio
    Tanaka, Sakae
    Kawano, Hirotaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 548 - 553
  • [3] Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis
    Yusuke Tsuda
    Tohru Nakagawa
    Yusuke Shinoda
    Atsushi Kanatani
    Taketo Kawai
    Satoru Taguchi
    Yukio Yamada
    Ryoko Sawada
    Haruki Kume
    Yukio Homma
    Sakae Tanaka
    Hirotaka Kawano
    International Journal of Clinical Oncology, 2017, 22 : 548 - 553
  • [4] Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases
    Ulas, Arife
    Bilici, Ahmet
    Durnali, Ayse
    Tokluoglu, Saadet
    Akinci, Sema
    Silay, Kamile
    Oksuzoglu, Berna
    Alkis, Necati
    TUMOR BIOLOGY, 2016, 37 (01) : 1131 - 1140
  • [5] Prognostic factors and skeletal-related events in patients with bone metastasis from gastric cancer
    Imura, Yoshinori
    Tateiwa, Daisuke
    Sugimoto, Naotoshi
    Inoue, Akitomo
    Wakamatsu, Toru
    Outani, Hidetatsu
    Tanaka, Takaaki
    Tamiya, Hironari
    Yagi, Toshinari
    Naka, Norifumi
    Okawa, Sumiyo
    Tabuchi, Takahiro
    Takenaka, Satoshi
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (04) : 1 - 8
  • [6] The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer
    Delea, T
    Langer, C
    McKiernan, J
    Liss, M
    Edelsberg, J
    Brandman, J
    Sung, J
    Raut, M
    Oster, G
    ONCOLOGY, 2004, 67 (5-6) : 390 - 396
  • [7] Skeletal-related events in urological cancer patients with bone metastasis: A multicenter study in Japan
    Yokomizo, Akira
    Koga, Hirofumi
    Shinohara, Nobuo
    Miyahara, Tsukasa
    Machida, Noriko
    Tsukino, Hiromasa
    Uozumi, Jiro
    Nishiyama, Kenryu
    Satoh, Fuminori
    Sakai, Hideki
    Naito, Seiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (04) : 332 - 336
  • [8] Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis from Solid Tumor
    Iranikhah, Maryam
    Wilborn, Teresa W.
    Wensel, Terri M.
    Ferrell, Jodi B.
    PHARMACOTHERAPY, 2012, 32 (03): : 274 - 284
  • [9] Multidisciplinary approach for preventing skeletal-related events in patients with bone metastasis
    Ito, Shigeki
    Suzuki, Tomohiro
    Ariga, Hisanori
    Murakami, Hideki
    Kimura, Yusuke
    Endo, Hirooki
    Nakayama, Manabu
    Ishida, Kazuyuki
    Sugai, Tamotsu
    Ehara, Shigeru
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases
    Sun, Jong-Mu
    Ahn, Jin Seok
    Lee, Soohyeon
    Kim, Jung A.
    Lee, Jeeyun
    Park, Yeon Hee
    Park, Hee Chul
    Ahn, Myung-Ju
    Ahn, Yong Chan
    Park, Keunchil
    LUNG CANCER, 2011, 71 (01) : 89 - 93